Abstract
The article presents current data on etiology and pathogenesis rosacea, listed endogenous and exogenous provoking factors. The pathogenetic justification given of the use of botulinum toxin type A in erythematosus-teleangiectatic subtype rosacea. A study involving 32 patients with ETP was carried out, during which a combination treatment was used – a course of microcurrent therapy followed by botulinum therapy by mesotechnics (in two different breedings). According to the results of the study, a pronounced clinical effect was established in patients. The results were evaluated using an analog VAS scale as well as DIQL. We came to conclusions about the effectiveness of combined use of microcurrent therapy and botulinum therapy in erythematosus-teleangiectatic subtype rosacea and the feasibility of further study of this issue.
Highlights
The pathogenetic justification given of the use of botulinum toxin type A in erythematosus-teleangiectatic subtype rosacea
A study involving 32 patients with ETP was carried out, during which a combination treatment was used – a course of microcurrent therapy followed by botulinum therapy by mesotechnics
According to the results of the study, a pronounced clinical effect was established in patients
Summary
Acta Dermatol Venereol (Stockh) 1992; 72: 373–375. I. Profile of alopecia areata: a questionaire analysis of patients and family. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. 8. Alfani S, Antinone V, Mozzetta A, Di Pietro C, Mazzanti C, Stella P, et al Psychological status of patients with alopecia areata. Дано патогенетическое обоснование целесообразности применения ботулинического токсина типа А при эритематозно-телеангиэктатическом подтипе розацеа. Пришли к выводам об эффективности комбинированного применения микротоковой терапии и ботулинотерапии при эритематозно-телеангиэктатическом подтипе розацеа и целесообразности дальнейшего изучения данного вопроса. We came to conclusions about the effectiveness of combined use of microcurrent therapy and botulinum therapy in erythematosus-teleangiectatic subtype rosacea and the feasibility of further study of this issue.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have